Abstract 4462
Background
Lung cancer is the leading cause of cancer mortality worldwide with more than 2 million new cases and 1.8 million deaths in 2018. The TTR could be of use to objectively understand the clinical reality of lung cancer in Spain.
Methods
Observational cohort multicenter study performed in Spain. Enrollment took place between Aug’16 and Dec’18. Evaluation included a review of demographic data.
Results
6600 patients in 56 Spanish hospitals were included. Median age at diagnosis was 64 in advanced disease and 65 in early-stage. The majority of patients presented with advanced, stage III (n = 1874, 28.4%) or IV (n = 3446, 52.2%) at diagnosis, independently of gender (63.1% in males; 70.6% in females). There was a higher number of patients with no comorbidities at diagnosis in advanced disease than in early-stage (63.4% vs. 36.6%, p < 0.001) Significant differences (p < 0.001, unless indicated) observed between the two groups in the prevalence of cardiopathy, dyslipidemia (p = 0.043), COPD, hypercholesterolemia (p = 0.026), hypertension, nephropathy (p = 0.012), obesity (p = 0.007) and vasculopathy. Prevalence of symptoms (cough, pain, dyspnea, hemoptysis, weight loss, anorexia, and asthenia) was higher (p < 0.001) in advanced disease. No association found between professional occupation and stage at diagnosis, but according to exposure to carcinogenic compounds. A higher % of patients with advanced disease was observed over exposed to arsenic compounds (87.5% vs. 65.1%, p = 0.02) and acrylonitrile (75.0% vs. 65.1%, p = 0.02). Early-stage disease more prevalent among patients exposed to asbestos (47.5% vs. 34.9%, p = 0.02), radon/silica (47.4% vs. 34.9%, p = 0.02) and paintings (38.1% vs. 34.9%, p = 0.02) and diesel smoke (38.2% vs. 34.9%, p = 0.02) More patients with personal history of cancer had early-stage vs advanced disease (47.6% vs. 34.9%, p < 0.001); no differences found in stage according to family history of cancer.
Conclusions
The RTT provides information on comorbidities, risk associations, personal and family history of cancer necessary for the knowledge of lung cancer in real life, which could even be useful when planning the analysis of national health policies.
Clinical trial identification
NCT02941458.
Editorial acknowledgement
Legal entity responsible for the study
Spanish Lung Cancer Group.
Funding
Novartis, MSD, Lilly.
Disclosure
M. Provencio: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract